Novo Nordisk Files MAA for Semaglutide to the EMA for Type 2 Diabetes

Shots:

• The submission is based on 10 PIONEER studies assessing semaglutide vs sitagliptin, empagliflozin, liraglutide and dulaglutide in 9,543 adult patients with type 2 diabetes
• The collective studies result demonstrated reduction in HbA_1c and weight loss with safe & well tolerated data
• Semaglutide (qd) is an oral GLP-1 receptor agonist administered once-daily with its expected approval in the US, the EU and Canada

Click here to read full press release/ article | Ref: Novo Nordisk | Image: The Local Denmark